John L Reagan

Trials

Studies that name John L Reagan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:46 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07153497 · Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

  National Cancer Institute (NCI) · not yet recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Alliance for Clinical Trials in Oncology Member Site Core
  U10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026
  Named on NCT07153497